Pluristem

bioreactor pluristem
Israel's Pluristem FDA approved for study in treatment of severe COVID-19

Six critically ill coronavirus patients in Israel who were considered high-risk for mortality were treated with Pluristem and survived.

Israel's Pluristem secures €50m. EU financing to boost COVID-19 treatment

The financing is backed by a guarantee from the European Fund for Strategic Investments (EFSI), the financial pillar of the European Union's Investment Plan for Europe.

25/04/2020
A Pluristem scientist in the process of making its cell products and a look at the final product its
Israeli COVID-19 treatment with 100% survival rate tested on US patient

After one week, six critically ill patients in Israel survived. Four of them showed improvement in respiratory parameters.

Biologists work in a laboratory at Pluristem Therapeutics Inc. in Haifa
Israeli COVID-19 treatment shows 100% survival rate - preliminary data

Not only have all the patients survived, according to Pluristem, but four of them showed improvement in respiratory parameters.

Biologists work in a laboratory at Pluristem Therapeutics Inc. in Haifa
Pluristem’s potential new breakthrough

Haifa company weeks away from presenting clinical trial results that could ‘generate hope’ for patients suffering from untreatable vascular disease.

By MAAYAN HOFFMAN
27/05/2018
Smart cells that heal

Innovative Israeli cell therapy could step up treatment of CLI.

By MAAYAN HOFFMAN
14/02/2018
Pluristen chairman and co-CEO Zami Aberman holds a vial of specialized stem cells the company calls
New hope for cancer patients

Cancer is a leading cause of death around the world and its incidence continues to rise. Each year around 12.7 million people discover they have cancer and 7.6 million people die from it.

By MAAYAN HOFFMAN
12/01/2018
A Pluristem scientist in the process of making its cell products and a look at the final product its
USFDA clears Plursitem for expanded access program

Patients suffering from critical limb ischemia can now benefit without being part of clinical trials

By DAVID BRUMMER
10/01/2018
Subscribe for our daily newsletter
Subscribe for our daily newsletter

By subscribing I accept the terms of use